About the speaker: Anselme L. Perrier is a research director at the French National Institute of Health and Medical Research (Inserm). A.L Perrier is a developmental neurobiologist and neuroscientist at the Institute for stem cell therapy and exploration of monogenic diseases (I-Stem). He is currently the head of the neurodegenerative diseases group of the Inserm/UEVE U861 at I-Stem.
A.L Perrier graduated from the Ecole Normale Supérieure de Lyon in 1998 and earned his doctoral degree in Neuropharmacology in 2001 at the University Pierre & Marie Curie in Paris. He did his doctoral research work in Dr Massoulié’s laboratory at the Ecole Normale Supérieure in Paris where he investigated the molecular basis of the membrane localization of acetylcholinesterase in mammalian brain. Next, he joined, as a postdoc, Dr Studer’s lab at the Memorial Sloan Kettering Cancer Center in New-York (USA) where he mostly worked on human embryonic stem cells (hESC) differentiation into ventral mesencephalic dopaminergic neurons in the context of the development of Parkinson’s disease stem cell therapy. In 2004, AL Perrier joined Dr Peschanski’s lab (Creteil, France) and was the first post-doc recruited to set up I-Stem and train the first members of the institute to work with hESC. He was recruited by the Inserm in 2005 and founded in 2007 an Inserm research group dedicated to neurodegenerative disorders focusing in particular on Huntington’s disease (HD). Over the years, AL Perrier has established novel strategies for developing specific neuronal cell populations from human pluripotent stem cells (most notably striatal projection neurons) and he has used such derivatives as valuable tools for disease modelling, drug discovery and to develop cell therapy approach for HD.
Click the links below to download the attachments: